Compare LCUT & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCUT | CRDL |
|---|---|---|
| Founded | 1945 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.2M | 154.1M |
| IPO Year | 1996 | 2017 |
| Metric | LCUT | CRDL |
|---|---|---|
| Price | $7.33 | $1.36 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $8.50 |
| AVG Volume (30 Days) | 170.3K | ★ 893.5K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $647,933,000.00 | N/A |
| Revenue This Year | $3.74 | N/A |
| Revenue Next Year | $1.20 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.89 | $0.88 |
| 52 Week High | $8.20 | $1.71 |
| Indicator | LCUT | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 61.92 | 51.58 |
| Support Level | $3.45 | $0.95 |
| Resistance Level | $8.20 | $1.43 |
| Average True Range (ATR) | 0.60 | 0.11 |
| MACD | -0.12 | -0.02 |
| Stochastic Oscillator | 48.78 | 16.67 |
Lifetime Brands Inc is a U.S.-based company that designs, sources, and sells branded kitchenware, tableware, and other home solution products used in the home. The company's product portfolio comprises kitchen tools, cutlery, thermometers, cutting boards, spice racks, dinnerware, stemware, flatware, bath scales, thermal beverage ware, food storage, neoprene travel products, etc. These products are marketed under owned or licensed brands like Farberware, KitchenAid, Mikasa, Misto, Taylor, Sabatier, and Pfaltzgraff, among others. The company mainly sells its products directly to retailers and distributors, and a limited selection directly to consumers through its own websites. It has two reportable operating segments: U.S., which derives maximum revenue, and International.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.